{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T12:54:40Z","timestamp":1789736080231,"version":"4.0.1"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,10,23]]},"DOI":"10.1097\/qad.0b013e32833ea9bc","type":"journal-article","created":{"date-parts":[[2010,9,8]],"date-time":"2010-09-08T07:03:28Z","timestamp":1283929408000},"page":"2507-2515","source":"Crossref","is-referenced-by-count":22,"title":["Uridine supplementation in the treatment of HIV lipoatrophy: results of ACTG 5229"],"prefix":"10.1097","volume":"24","author":[{"given":"Grace A","family":"McComsey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich A","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chakra B","family":"Budhathoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohui","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith S","family":"Currier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Kosmiski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda G","family":"Naini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phannie","family":"Charles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Medvik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith A","family":"Aberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-10-20210130","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1097\/00002030-200306130-00007","article-title":"Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy","volume":"17","author":"Nolan","year":"2003","journal-title":"AIDS"},{"key":"R2-10-20210130","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/00042560-200202010-00002","article-title":"Evidence of nucleoside analogue reverse transcriptase inhibitor: associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patients","volume":"29","author":"Walker","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R3-10-20210130","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.mito.2004.05.008","article-title":"Role of mitochondria in HIV lipoatrophy: insight into pathogenesis and potential therapies","volume":"4","author":"McComsey","year":"2004","journal-title":"Mitochondrion"},{"key":"R4-10-20210130","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1086\/380790","article-title":"Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study","volume":"38","author":"McComsey","year":"2004","journal-title":"Clin Infect Dis"},{"key":"R5-10-20210130","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/00002030-200404300-00011","article-title":"Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study","volume":"18","author":"Martin","year":"2004","journal-title":"AIDS"},{"key":"R6-10-20210130","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1097\/01.aids.0000247574.33998.03","article-title":"A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy","volume":"20","author":"Moyle","year":"2006","journal-title":"AIDS"},{"key":"R7-10-20210130","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1177\/135965350300800514","article-title":"Uridine abrogates mitochondrial toxicity related to nucleoside analogue reverse transcriptase inhibitors in HepG2 cells","volume":"8","author":"Walker","year":"2003","journal-title":"Antivir Ther"},{"key":"R8-10-20210130","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/135965350601100109","article-title":"Uridine abrogates the adverse effects of antiretroviral pyrimidine analogues on adipose cell functions","volume":"11","author":"Walker","year":"2006","journal-title":"Antivir Ther"},{"key":"R9-10-20210130","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/135965350701200113","article-title":"Uridine supplementation for the treatment of antiretroviral therapy-associated lipoatrophy: a randomized, double-blind, placebo-controlled trial","volume":"12","author":"Sutinen","year":"2007","journal-title":"Antivir Ther"},{"key":"R10-10-20210130","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1038\/sj.ejcn.1602793","article-title":"Uridine supplementation in HIV lipoatrophy: pilot trial on safety and effect on mitochondrial indices","volume":"62","author":"McComsey","year":"2008","journal-title":"Eur J Clin Nutr"},{"key":"R11-10-20210130","first-page":"745","article-title":"Clinical and pharmacokinetic studies of prolonged administration of high-dose uridine intended for rescue from 5-FU toxicity","volume":"70","author":"van Groeningen","year":"1986","journal-title":"Cancer Treat Rep"},{"issue":"12","key":"R12-10-20210130","first-page":"5928","article-title":"Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity","volume":"44","author":"Leyva","year":"1984","journal-title":"Cancer Res"},{"key":"R14-10-20210130","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1182\/blood.V76.11.2210.2210","article-title":"Benzylacyclouridine reverses azidothymidine-induced marrow suppression without impairment of antihuman immunodeficiency virus activity","volume":"76","author":"Calabresi","year":"1990","journal-title":"Blood"},{"key":"R15-10-20210130","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1177\/135965350300800516","article-title":"Uridine excess does not interfere with the antiretroviral efficacy of nucleoside analogue reverse transcriptase inhibitors","volume":"8","author":"Koch","year":"2003","journal-title":"Antivir Ther"},{"key":"R16-10-20210130","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1097\/01.aids.0000166101.44262.52","article-title":"Uridine pharmacokinetics of mitocnol, a sugar cane extract","volume":"19","author":"Venhoff","year":"2005","journal-title":"AIDS"},{"key":"R17-10-20210130","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/hep.21490","article-title":"Uridine supplementation antagonizes zalcitabine-induced microvesicular steatohepatitis in mice","volume":"45","author":"Lebrecht","year":"2007","journal-title":"Hepatology"},{"key":"R19-10-20210130","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/QAI.0b013e3181ae2eb9","article-title":"A randomized comparative trial of continued zidovudine\/lamivudine or replacement with tenofovir disoproxil fumarate\/emtricitabine in efavirenz-treated HIV-1-infected individuals","volume":"51","author":"Fisher","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R20-10-20210130","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/978-1-4684-8559-2_34","article-title":"Purine and pyrimidine metabolism in hereditary oroticaciduria during a 15 year follow-up study","volume":"122B","author":"Webster","year":"1979","journal-title":"Adv Exp Med Biol"},{"key":"R21-10-20210130","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1023\/A:1005357622551","article-title":"A longitudinal study of cognitive functioning in patients with classical galactosaemia, including a cohort treated with oral uridine","volume":"20","author":"Manis","year":"1997","journal-title":"J Inherit Metab Dis"}],"container-title":["AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00002030-201010230-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:39:32Z","timestamp":1786041572000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002030-201010230-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,23]]},"references-count":19,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/qad.0b013e32833ea9bc","relation":{},"ISSN":["0269-9370"],"issn-type":[{"value":"0269-9370","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10,23]]}}}